Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 264

    1.

    Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?

    Friedrich JO, Adhikari NK, Meade MO.

    Crit Care. 2006;10(3):145. Epub 2006 Jun 2. Review.

    PMID:
    16762040
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis.

    Vincent JL, O'Brien J Jr, Wheeler A, Wittebole X, Garg R, Trzaskoma BL, Sundin DP.

    Crit Care. 2006;10(3):R74. Epub 2006 May 9.

    PMID:
    16684364
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    3.

    Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.

    Laterre PF, Macias WL, Janes J, Williams MD, Nelson DR, Girbes AR, Dhainaut JF, Abraham E.

    Crit Care. 2008;12(5):R117. Epub 2008 Sep 11.

    PMID:
    18786266
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    4.

    International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

    Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, McL Booth FV.

    Surgery. 2006 Nov;140(5):726-39. Corrected and republished in: Surgery. 2007 Apr;141(4):548-61.

    PMID:
    17084715
    [PubMed - indexed for MEDLINE]
    5.

    International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

    Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, Booth FV.

    Surgery. 2007 Apr;141(4):548-61.

    PMID:
    17431957
    [PubMed - indexed for MEDLINE]
    6.

    Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.

    Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR; PROWESS Investigators.

    Crit Care Med. 2003 Jan;31(1):12-9.

    PMID:
    12544987
    [PubMed - indexed for MEDLINE]
    7.

    Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.

    De Backer D.

    Drug Saf. 2007;30(11):995-1010. Review.

    PMID:
    17973539
    [PubMed - indexed for MEDLINE]
    8.

    Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.

    [No authors listed]

    Prescrire Int. 2007 Feb;16(87):7-9.

    PMID:
    17323514
    [PubMed - indexed for MEDLINE]
    9.

    Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.

    Bernard GR, Margolis BD, Shanies HM, Ely EW, Wheeler AP, Levy H, Wong K, Wright TJ; Extended Evaluation of Recombinant Human Activated Protein C United States Investigators.

    Chest. 2004 Jun;125(6):2206-16.

    PMID:
    15189943
    [PubMed - indexed for MEDLINE]
    Free Article
    10.

    Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.

    Barie PS, Hydo LJ, Shou J, Eachempati SR.

    Surg Infect (Larchmt). 2006;7 Suppl 2:S77-80. Review.

    PMID:
    16895513
    [PubMed - indexed for MEDLINE]
    11.

    Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study.

    Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SC, Dhainaut JF; PROWESS Clinical Evaluation Committee.

    Crit Care Med. 2005 May;33(5):952-61.

    PMID:
    15891319
    [PubMed - indexed for MEDLINE]
    12.

    A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.

    Wheeler A, Steingrub J, Schmidt GA, Sanchez P, Jacobi J, Linde-Zwirble W, Bates B, Qualy RL, Woodward B, Zeckel M.

    Crit Care Med. 2008 Jan;36(1):14-23.

    PMID:
    18158435
    [PubMed - indexed for MEDLINE]
    13.

    The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

    Angus DC, Laterre PF, Helterbrand J, Ely EW, Ball DE, Garg R, Weissfeld LA, Bernard GR; PROWESS Investigators.

    Crit Care Med. 2004 Nov;32(11):2199-206.

    PMID:
    15640631
    [PubMed - indexed for MEDLINE]
    14.

    Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

    Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group.

    N Engl J Med. 2005 Sep 29;353(13):1332-41.

    PMID:
    16192478
    [PubMed - indexed for MEDLINE]
    Free Article
    15.

    Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.

    Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson G 3rd, Bernard GR; Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group.

    Crit Care Med. 2003 Mar;31(3):834-40.

    PMID:
    12626993
    [PubMed - indexed for MEDLINE]
    16.

    Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.

    McCoy C.

    Expert Opin Drug Saf. 2004 Nov;3(6):625-37. Review.

    PMID:
    15500421
    [PubMed - indexed for MEDLINE]
    17.

    Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.

    Frampton JE, Foster RH.

    Pharmacoeconomics. 2004;22(7):445-76. Review.

    PMID:
    15137883
    [PubMed - indexed for MEDLINE]
    18.

    International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH.

    Sashegyi A, Trzaskoma BL, Nelson DR, Williams MD, Macias W.

    Curr Med Res Opin. 2006 May;22(5):1001-12.

    PMID:
    16709322
    [PubMed - indexed for MEDLINE]
    19.

    Efficacy and safety of recombinant human activated protein C for severe sepsis.

    Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group.

    N Engl J Med. 2001 Mar 8;344(10):699-709.

    PMID:
    11236773
    [PubMed - indexed for MEDLINE]
    Free Article
    20.

    Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy.

    Sollet JP, Garber GE.

    Am J Surg. 2002 Dec;184(6A Suppl):S11-8.

    PMID:
    12521613
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk